Venetoclax Combination Therapy for Leukemia
Trial Summary
What is the purpose of this trial?
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with newly diagnosed B cell acute lymphoblastic leukemia. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. The C10403 regimen is composed of the chemotherapy drugs cytarabine, cyclophosphamide, daunorubicin, mercaptopurine, pegaspargase, vincristine, and methotrexate, all which work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It also consists of prednisone, which is an anti-inflammatory drug that lowers the body's immune response and is used with other drugs in the treatment of some types of some types of cancer. This study may help researchers learn if adding venetoclax to the pediatric-inspired C10403 regimen can be tolerated and help treat older patients.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot take strong or moderate CYP3A4 inducers within 14 days before starting the trial. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
What data supports the effectiveness of the drug Venetoclax for leukemia?
Venetoclax has shown effectiveness in treating chronic lymphocytic leukemia (CLL), achieving high response rates and longer progression-free survival when used in combination with other drugs like obinutuzumab and rituximab. It is also being developed for use in acute myeloid leukemia and other blood cancers, indicating its potential effectiveness in various types of leukemia.12345
What safety data exists for Venetoclax combination therapy in humans?
Venetoclax, also known as Venclexta, has been shown to have an acceptable safety profile in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Common side effects include myelosuppression (a decrease in bone marrow activity) and neutropenia (low levels of a type of white blood cell), which can be managed with supportive care and dose adjustments. No new safety concerns were identified in children and adolescents with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).12567
What makes Venetoclax combination therapy unique for treating leukemia?
Venetoclax is unique because it specifically targets and inhibits a protein called BCL-2, which helps cancer cells survive, making it different from traditional chemotherapy that targets rapidly dividing cells. This targeted approach can potentially lead to fewer side effects and improved effectiveness in treating leukemia.89101112
Eligibility Criteria
Adults aged 18-54 with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) can join this trial. They must be in good physical condition, not pregnant or breastfeeding, and willing to use non-hormonal birth control. People with certain heart conditions, other cancers, uncontrolled infections or those who have taken strong medications that affect liver enzymes recently cannot participate.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Induction
Patients receive venetoclax and a combination of chemotherapy drugs including cytarabine, prednisone, vincristine, daunorubicin, pegaspargase, and methotrexate
Extended Induction
Patients continue to receive venetoclax and chemotherapy drugs if they have stable disease or partial response after initial induction
Consolidation
Patients receive venetoclax and a combination of chemotherapy drugs including cyclophosphamide, cytarabine, mercaptopurine, vincristine, pegaspargase, and methotrexate
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- C10403 (Chemotherapy)
- Venetoclax (Bcl-2 Inhibitor)